MX2023007404A - Métodos para preparar moduladores del receptor de glucocorticoides de azadecalina fusionados con heteroaril-cetona. - Google Patents

Métodos para preparar moduladores del receptor de glucocorticoides de azadecalina fusionados con heteroaril-cetona.

Info

Publication number
MX2023007404A
MX2023007404A MX2023007404A MX2023007404A MX2023007404A MX 2023007404 A MX2023007404 A MX 2023007404A MX 2023007404 A MX2023007404 A MX 2023007404A MX 2023007404 A MX2023007404 A MX 2023007404A MX 2023007404 A MX2023007404 A MX 2023007404A
Authority
MX
Mexico
Prior art keywords
receptor modulators
glucocorticoid receptor
methods
fused azadecalin
ketone fused
Prior art date
Application number
MX2023007404A
Other languages
English (en)
Spanish (es)
Inventor
Travis Lemons
Jeffrey Mark Dener
Hazel Joan Hunt
Gary Reid
Kilian Garrec
Thomas C Stephens
Adam Daisuke Gammack Yamagata
Yunguo Lu
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2023007404A publication Critical patent/MX2023007404A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023007404A 2020-12-25 2021-12-22 Métodos para preparar moduladores del receptor de glucocorticoides de azadecalina fusionados con heteroaril-cetona. MX2023007404A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/139524 WO2022134033A1 (en) 2020-12-25 2020-12-25 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PCT/US2021/064947 WO2022140600A1 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
MX2023007404A true MX2023007404A (es) 2023-08-21

Family

ID=82157262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007404A MX2023007404A (es) 2020-12-25 2021-12-22 Métodos para preparar moduladores del receptor de glucocorticoides de azadecalina fusionados con heteroaril-cetona.

Country Status (10)

Country Link
US (2) US12152028B2 (enExample)
EP (1) EP4267577A4 (enExample)
JP (1) JP7720914B2 (enExample)
KR (1) KR20230124985A (enExample)
CN (1) CN116867780A (enExample)
AU (2) AU2021410756B2 (enExample)
CA (1) CA3202354A1 (enExample)
IL (1) IL304005A (enExample)
MX (1) MX2023007404A (enExample)
WO (2) WO2022134033A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72729A (en) 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DE69430373T2 (de) 1993-08-06 2002-12-12 Smithkline Beecham S.P.A., Baranzate Di Bollate Hydroisochinolinderivate
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
EP1061919A4 (en) 1998-03-10 2002-09-04 Res Triangle Inst NOVEL OPIOUS COMPOUNDS AND PROCESSES FOR THEIR PREPARATION AND USE
US6166013A (en) 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
WO2000043017A1 (en) 1999-01-21 2000-07-27 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
GB0010683D0 (en) 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
AU2002258399A1 (en) 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
JP2004537563A (ja) 2001-07-23 2004-12-16 コーセプト セラピューティクス， インコーポレイテッド 抗神経病薬誘導性体重増加を予防するための方法
CN1556708A (zh) 2001-08-31 2004-12-22 �Ƹ��� 抑制成年唐氏综合症患者认知退化的方法
AU2003214879B2 (en) 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP2005535664A (ja) 2002-07-02 2005-11-24 コーセプト セラピューティクス， インコーポレイテッド インターフェロン−α治療に関連した精神病を処置するための方法
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
US20040229855A1 (en) 2003-02-04 2004-11-18 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
DK1761497T3 (da) 2004-01-09 2008-11-03 Corcept Therapeutics Inc Azadecalinglucocorticoidreceptormodulatorer
AU2005217646A1 (en) 2004-02-26 2005-09-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A novel cofactor that modulates steroid receptor activities
AU2005222421B2 (en) 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
JP4958774B2 (ja) 2004-07-02 2012-06-20 コーセプト セラピューティクス， インコーポレイテッド 改変されたピリミジン糖質コルチコイドレセプター調節因子
EP2757099B1 (en) 2005-05-12 2017-08-23 AbbVie Bahamas Limited Apoptosis promoters
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
US20120022121A1 (en) 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
CA2728563C (en) 2008-07-01 2017-05-30 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of amyotrophic lateral sclerosis
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
JP5637568B2 (ja) 2009-05-12 2014-12-10 コーセプト セラピューティクス， インコーポレイテッド 固体形態および調製のためのプロセス
EP2545173A2 (en) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
MX2013002186A (es) 2010-08-27 2013-06-28 Corcept Therapeutics Inc Moduladores de azadecalina de piridil-amina fusionada.
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
EP2671086B1 (en) 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
KR101925955B1 (ko) 2011-03-18 2018-12-06 코어셉트 쎄라퓨틱스, 잉크. 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
ES2665580T3 (es) 2011-11-11 2018-04-26 Gilead Apollo, Llc Inhibidores de ACC y usos de los mismos
PT3111950T (pt) 2012-02-24 2021-10-19 Univ Chicago Métodos e composições relacionadas com antagonismo recetor de glucocorticoide e cancro da próstata
US20130225633A1 (en) 2012-02-27 2013-08-29 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
PT3338781T (pt) * 2012-05-25 2019-11-29 Corcept Therapeutics Inc Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetonas
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP4219494B1 (en) 2013-11-25 2026-03-25 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
US9452255B2 (en) 2014-07-21 2016-09-27 Medtronic Minimed, Inc. Smart connection interface
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US10047157B2 (en) 2014-12-19 2018-08-14 Alder Biopharmaceuticals, Inc. Humanized anti-ACTH antibodies and use thereof
WO2016140867A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
WO2016141365A1 (en) 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
MX390517B (es) * 2016-03-01 2025-03-20 Corcept Therapeutics Inc Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
PH12017000049A1 (en) 2017-02-20 2018-08-29 S Heilveil Peter Aerial cable spacer
SG11201908790PA (en) 2017-03-31 2019-10-30 Corcept Therapeutics Inc Glucocorticoid receptor modulators to treat cervical cancer
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
CA3131263C (en) * 2019-02-22 2024-01-02 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
EP4103180A4 (en) 2020-02-10 2024-03-13 Corcept Therapeutics Incorporated METHOD FOR STIMULATING AN ANTI-TUMOR RESPONSE USING A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL317734A (en) 2022-06-28 2025-02-01 Corcept Therapeutics Inc METHODS FOR PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Also Published As

Publication number Publication date
AU2021410756A1 (en) 2023-07-06
EP4267577A4 (en) 2024-11-27
WO2022140600A1 (en) 2022-06-30
JP2024501956A (ja) 2024-01-17
CN116867780A (zh) 2023-10-10
CA3202354A1 (en) 2022-06-30
US12152028B2 (en) 2024-11-26
AU2021410756A9 (en) 2024-09-12
US20220227753A1 (en) 2022-07-21
JP7720914B2 (ja) 2025-08-08
US20250145620A1 (en) 2025-05-08
KR20230124985A (ko) 2023-08-28
AU2025203341B2 (en) 2026-03-05
EP4267577A1 (en) 2023-11-01
IL304005A (en) 2023-08-01
AU2025203341A1 (en) 2025-05-29
WO2022134033A1 (en) 2022-06-30
AU2021410756B2 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
MX2024014832A (es) Métodos para preparar moduladores del receptor de glucocorticoides de azadecalina fusionados con heteroaril-cetona
PH12022551524A1 (en) Irak degraders and uses thereof
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
PH12023500015A1 (en) Irak degraders and uses thereof
PH12021500026A1 (en) Irak degraders and uses thereof
PH12021553018A1 (en) New egfr inhibitors
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
WO2020243415A3 (en) Tead inhibitors and uses thereof
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
EP4451781A3 (en) Uu based sidelink control for nr v2x
EP4488286A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
ZA201906822B (en) Indole ahr inhibitors and uses thereof
CR20200239A (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
WO2020160193A3 (en) Compounds and uses thereof
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
ZA202309516B (en) Anti-ccr8 antibodies
MX2021006564A (es) Sistemas activos dinamicos acromosomicos.
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2022005091A (es) Metodos de preparacion de una muestra enriquecida para la secuenciacion de polipeptidos.
EP4302827A3 (en) Rapamycin analogs and uses thereof